Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 1 of 6
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS
`USA, INC.,
`
`
`Plaintiffs,
`
`
`v.
`
`ELI LILLY AND COMPANY,
`
`
`Defendant.
`
`
`
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`
`
`
`
`
`STIPULATION AND [PROPOSED] ORDER REGARDING ASSERTED CLAIMS
`
`Plaintiffs Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.
`
`(collectively, “Teva”) and Defendant Eli Lilly and Company (“Lilly”) (all together, the “Parties”)
`
`have agreed to enter into this stipulation to streamline the issues in dispute in this matter, subject
`
`to the approval of the Court;
`
`WHEREAS, Teva has asserted claims 17, 18, 19, 20, 21, 24, 27, and 30 of U.S. Patent
`
`No. 8,586,045 (“the ’045 patent”); claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,907 (“the
`
`’907 patent”); and claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,908 (“the ’908 patent”)
`
`against Lilly; and
`
`WHEREAS, on October 3, 2022, the Court entered a Memorandum and Order On Cross-
`
`Motions for Summary Judgment (ECF No. 513), granting Lilly’s motion for partial summary
`
`judgment of non-infringement with respect to claims 18 and 21 of the ’045 patent;1
`
`
`1 Teva reserves all appellate rights with respect to the October 3, 2022 summary judgment decision,
`ECF No 513, and claims 18 and 21 of the ʼ045 patent.
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS
`USA, INC.,
`
`
`Plaintiffs,
`
`
`v.
`
`ELI LILLY AND COMPANY,
`
`
`Defendant.
`
`
`
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`
`
`
`
`
`STIPULATION AND [PROPOSED] ORDER REGARDING ASSERTED CLAIMS
`
`Plaintiffs Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.
`
`(collectively, “Teva”) and Defendant Eli Lilly and Company (“Lilly”) (all together, the “Parties”)
`
`have agreed to enter into this stipulation to streamline the issues in dispute in this matter, subject
`
`to the approval of the Court;
`
`WHEREAS, Teva has asserted claims 17, 18, 19, 20, 21, 24, 27, and 30 of U.S. Patent
`
`No. 8,586,045 (“the ’045 patent”); claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,907 (“the
`
`’907 patent”); and claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,908 (“the ’908 patent”)
`
`against Lilly; and
`
`WHEREAS, on October 3, 2022, the Court entered a Memorandum and Order On Cross-
`
`Motions for Summary Judgment (ECF No. 513), granting Lilly’s motion for partial summary
`
`judgment of non-infringement with respect to claims 18 and 21 of the ’045 patent;1
`
`
`1 Teva reserves all appellate rights with respect to the October 3, 2022 summary judgment decision,
`ECF No 513, and claims 18 and 21 of the ʼ045 patent.
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 2 of 6
`
`WHEREAS, in view of the Court’s order granting partial summary judgment of non-
`
`infringement with respect to claims 18 and 21 of the ’045 patent, Lilly will agree to dismiss its
`
`counterclaims of invalidity with respect to claims 18 and 21 of the ’045 patent without prejudice;
`
`and
`
`WHEREAS, the Parties seek to further reduce the number of claims and defenses to
`
`streamline the issues for trial, and accordingly hereby agree to dismiss certain claims and certain
`
`corresponding counterclaims and defenses.
`
`NOW THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and between
`
`the Parties hereto, and subject to the approval of the Court, as follows:
`
`1.
`
`Lilly stipulates that it voluntarily dismisses its counterclaims of invalidity
`
`pertaining to claims 18 and 21 of the ’045 patent without prejudice.
`
`2.
`
`Teva stipulates that it voluntarily dismisses its claims of infringement against Lilly
`
`of claims 17, 19, 20, 24, and 27 of the ʼ045 patent; claims 1, 4, 15, and 17 of the ʼ907 patent; and
`
`claims 1, 4, 15, and 17 of the ’908 patent pertaining to Lilly’s Emgality® (galcanezumab-gnlm)
`
`product with prejudice pursuant to Fed. R. Civ. P. 41(a)(2).
`
`3.
`
`Lilly stipulates that it voluntarily dismisses its defenses and counterclaims of
`
`invalidity and non-infringement pertaining to claims 17, 19, 20, 24, and 27 of the ʼ045 patent;
`
`claims 1, 4, 15, and 17 of the ʼ907 patent; and claims 1, 4, 15, and 17 of the ’908 patent with
`
`prejudice pursuant to Fed. R. Civ. P. 41(a)(2).2
`
`4.
`
`The Parties stipulate that they will continue to assert their respective claims (see
`
`ECF No. 1, Counts I, VI, VII, X, XV, and XVI), counterclaims (see ECF No. 277, Counterclaim
`
`
`2 For the avoidance of doubt, Lilly does not voluntarily dismiss its affirmative defenses and
`counterclaims of unclean hands and inequitable conduct, which apply to the entire patents, not
`individual patent claims.
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 3 of 6
`
`Counts I, II, XI–XIV, and XIX–XXI), and defenses (see ECF No. 277, Defenses 1, 2, 11–14, 20-
`
`25) with respect to only claims 30 of the ’045 patent; claims 5 and 6 of the ’907 patent; and claims
`
`5 and 6 of the ’908 patent.
`
`5.
`
`Without prejudice to any other claim or defense Lilly has in this action, including
`
`as to invalidity, unenforceability, no indirect infringement, and no willful infringement, Lilly
`
`stipulates and agrees that the use of Lilly’s Emgality® (galcanezumab-gnlm) product (described in
`
`BLA No. 761063) for the preventive treatment of migraine in the United States directly infringes
`
`under 35 U.S.C. § 271(a) claim 30 of the ’045 patent; claims 5 and 6 of the ’907 patent; and claims
`
`5 and 6 of the ’908 patent, under the Court’s Memorandum and Order on Claim Construction (ECF
`
`No. 101).3
`
`6.
`
`Without prejudice to any other claim or defense Lilly has in this action, including
`
`as to invalidity, unenforceability, no indirect infringement, and no willful infringement, Lilly
`
`stipulates and agrees that the use of Lilly’s Emgality® (galcanezumab-gnlm) product (described in
`
`BLA No. 761063) for the treatment of episodic cluster headache directly infringes under 35 U.S.C.
`
`§ 271(a) claim 30 of the ’045 patent; claim 5 of the ’907 patent; and claim 5 of the ’908 patent,
`
`under the Court’s Memorandum and Order on Claim Construction (ECF No. 101).
`
`IT IS SO ORDERED
`
`Dated:
`
`10/17/22
`
`Hon. Allison D. Burroughs
`United States District Judge
`
`3 For the avoidance of doubt, Lilly reserves all appellate rights with respect to the Memorandum
`and Order on Claim Construction (ECF No. 101).
`
`3
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 4 of 6
`
`Dated: October 17, 2022
`
`/s/ Elaine Herrmann Blais
`Douglas J. Kline (BBO# 556680)
`Elaine Herrmann Blais (BBO# 656142)
`Robert Frederickson III (BBO# 670111)
`Molly Grammel (BBO# 688439)
`Kevin P. Martin (BBO# 655222)
`Joshua S. Weinger (BBO# 690814)
`Alexandra Lu (BBO# 691114)
`Eric T. Romeo (BBO# 691591)
`Kathleen A. McGuinness (BBO# 693760)
`Tara R. Thigpen (BBO# 707508)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`dkline@goodwinlaw.com
`eblais@goodwinlaw.com
`rfrederickson@goodwinlaw.com
`mgrammel@goodwinlaw.com
`kmartin@goodwinlaw.com
`jweinger@goodwinlaw.com
`alu@goodwinlaw.com
`eromeo@goodwinlaw.com
`kmcguinness@goodwinlaw.com
`tthigpen@goodwinlaw.com
`
`Natasha E. Daughtrey (pro hac vice)
`Sean M. Anderson (pro hac vice)
`GOODWIN PROCTER LLP
`601 S. Figueroa St.
`Los Angeles, CA 90017
`Tel.: (213) 426-2500
`Fax: (213) 623-1673
`ndaughtrey@goodwinlaw.com
`sanderson@goodwinlaw.com
`
`
`Respectfully submitted,
`
`s/ Andrea L. Martin (with permission)
`Andrea L. Martin (BBO 666117)
`BURNS & LEVINSON LLP
`125 High Street
`Boston, MA 02110-1624
`(617) 345-3000
`amartin@burnslev.com
`
`Charles E. Lipsey
`Ryan O’Quinn
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`1875 Explorer Street
`Suite 800
`Reston, VA 20190-6023
`Charles.Lipsey@finnegan.com
`Oquinnr@finnegan.com
`
`Emily R. Gabranski
`Marta Garcia Daneshvar
`Lulu Wang
`Li Zhang
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`2 Seaport Lane
`Boston, MA 02210-2001
`Emily.Gabranski@finnegan.com
`Marta.Garcia@finnegan.com
`Lulu.Wang@finnegan.com
`Li.Zhang@finnegan.com
`
`William B. Raich
`Denise Main
`Danielle A. Duszczyszyn
`Pier D. DeRoo
`Matthew J. Luneack
`Yoonjin Lee
`Sydney Kestle
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`William.Raich@finnegan.com
`Denise.Main@finnegan.com
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 5 of 6
`
`Madeline R. DiLascia (pro hac vice)
`GOODWIN PROCTER LLP
`1900 N Street N.W.
`Washington, D.C. 20036
`Tel.: (202) 346-4000
`Fax: (202) 204-7250
`mdilascia@goodwinlaw.com
`
`Attorneys for Plaintiffs
`
`
`
`
`
`
`Danielle.Duszczyszyn@finnegan.com
`Pier.Deroo@finnegan.com
`Matthew.Luneack@finnegan.com
`Yoonjin.Lee@finnegan.com
`Sydney.Kestle@finnegan.com
`
`Attorneys for Defendant Eli Lilly and
`Company
`
`
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 6 of 6
`
`CERTIFICATE OF SERVICE
`
`I, Elaine Herrmann Blais, hereby certify that a copy of the foregoing document, filed
`
`through the CM/ECF system, will be sent electronically to the registered participants as identified
`
`on the Notice of Electronic Filing (“NEF”) and paper copies shall be served by first class mail
`
`postage prepaid on all counsel of record who are not served through the CM/ECF system on
`
`October 17, 2022.
`
`
`
`
`
`/s/ Elaine Herrmann Blais
`Elaine Herrmann Blais (BBO# 656142)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`(617) 570-1000
`eblais@goodwinlaw.com
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
